Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Alternate Health Club

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Alternate Health Club head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 211 · Grade C

Alternate Health Club

Visit Alternate Health Club Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 67 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Alternate Health Club a bad call — it's best for readers comparing a medication subscription who are comfortable with the standard intake review and can confirm any optional visit charges. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
58
Supply Reliability
95
76
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
77
Track Record
88
68
CoreAge RxBrief Score 94 · 67Alternate Health Club

Price, coverage & the tracker

CoreAge RxAlternate Health Club
Brief Score94/100 (A)67/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

From $129/month

Compounded semaglutide with B12; optional direct consultation $29.99.

Published vial supply: 28 days; billing is advertised monthly. Confirm payment dates and any additional selected services.

Full price details

Compounded semaglutide with B12 advertised from $129/month; published vial supply 28 days; optional direct provider consultation $29.99; confirm selected supply and required extras; earlier listing: From $129/mo (compounded)

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

From $169/month

Compounded tirzepatide with B12; optional direct consultation $29.99.

Published vial supply: 28 days; billing is advertised monthly. Confirm payment dates and any additional selected services.

Full price details

Compounded tirzepatide with B12 advertised from $169/month; published vial supply 28 days; optional direct provider consultation $29.99; confirm selected supply and required extras; earlier listing: From $169/mo (compounded)

CoverageUS only; restrictions by state, confirmed at intakeFAQ advertises telehealth throughout the USA; confirm clinician and pharmacy eligibility for your state and selected prescription
Brand-name accessNot confirmedThe checked weight-loss products are compounded preparations; approved medicines for other conditions do not establish a branded GLP-1 service.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Alternate Health Club: Semaglutide $129/month and tirzepatide $169/month are advertised medication rates; direct provider consultations are optional at $29.99.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.